Vascular endothelial growth factor D is dispensable for development of the lymphatic system

Molecular and Cellular Biology

Volumn 25, Issue 6, 2005, Pages 2441-2449

  Baldwin, Megan E ^a,e   Halford, Michael M ^a,f   Roufail, Sally ^a   Williams, Richard A ^b   Hibbs, Margaret L ^a   Grail, Dianne ^a   Kubo, Hajime ^c   Stacker, Steven A ^a   Achen, Marc G ^a,d  

^a OLIVIA NEWTON JOHN CANCER RESEARCH INSTITUTE   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c KYOTO UNIVERSITY   (Japan)

^d ROYAL MELBOURNE HOSPITAL   (Australia)

^e GENENTECH INC   (United States)

^f UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN; PROTEIN TYROSINE KINASE; VASCULOTROPIN C; VASCULOTROPIN D; VASCULOTROPIN RECEPTOR 3;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BODY MASS; BRONCHIOLE; CONTROLLED STUDY; EMBRYO; EMBRYO DEVELOPMENT; EMBRYONIC STEM CELL; FEMALE; GENE EXPRESSION; GENE TARGETING; GENE VECTOR; LUNG DEVELOPMENT; LYMPH VESSEL ENDOTHELIUM; LYMPHANGIOGENESIS; LYMPHATIC PARAMETERS; LYMPHATIC SYSTEM; MALE; MOUSE; MOUSE MUTANT; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN SECRETION; SIGNAL TRANSDUCTION; TISSUE STRUCTURE; WILD TYPE;

ANIMALS; ENDOTHELIUM, LYMPHATIC; GENE TARGETING; LUNG; LYMPHANGIOGENESIS; MICE; MICE, MUTANT STRAINS; MUTATION; VASCULAR ENDOTHELIAL GROWTH FACTOR D; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-3;

EID: 13844273017     PISSN: 02707306     EISSN: None     Source Type: Journal    
DOI: 10.1128/MCB.25.6.2441-2449.2005     Document Type: Article

References (47)

1. Achen, M. G., M. Jeltsch, E. Kukk, T. Mäkinen, A. Vitali, A. F. Wilks, K. Alitalo, and S. A. Stacker. 1998. Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk-1) and VEGF receptor 3 (Flt-4). Proc. Natl. Acad. Sci. USA 95:548-553.
2. Achen, M. G., S. Roufail, T. Domagala, B. Catimel, E. C. Nice, D. M. Geleick, R. Murphy, A. M. Scott, C. Caesar, T. Makinen, K. Alitalo, and S. A. Stacker. 2000. Monoclonal antibodies to vascular endothelial growth factor-D block interactions with both VEGF receptor-2 and VEGF receptor-3. Eur. J. Biochem. 267:2505-2515.
3. Achen, M. G., R. A. Williams, M. E. Baldwin, P. Lai, S. Roufail, K. Alitalo, and S. A. Stacker. 2002. The angiogenic and lymphangiogenic factor vascular endothelial growth factor-D exhibits a paracrine mode of action in cancer. Growth Factors 20:99-107.
4. Achen, M. G., R. A. Williams, M. P. Minekus, G. E. Thornton, K. Stenvers, P. A. W. Rogers, F. Lederman, S. Roufail, and S. A. Stacker. 2001. Localization of vascular endothelial growth factor-D in malignant melanoma suggests a role in tumour angiogenesis. J. Pathol. 193:147-154.
5. Avantaggiato, V., M. Orlandini, D. Acampora, S. Oliviero, and A. Simeone. 1998. Embryonic expression pattern of the marine figf gene, a growth factor belonging to platelet-derived growth factor/vascular endothelial growth factor family. Mech. Dev. 73:221-224.
6. Baldwin, M. E., B. Catimel, E. C. Nice, S. Roufail, N. E. Hall, K. L. Stenvers, M. J. Karkkainen, K. Alitalo, S. A. Stacker, and M. G. Achen. 2001. The specificity of receptor binding by vascular endothelial growth factor-D is different in mouse and man. J. Biol. Chem. 276:19166-19171.
7. Baldwin, M. E., S. Roufail, M. M. Halford, K. Alitalo, S. A. Stacker, and M. G. Achen. 2001. Multiple forms of mouse vascular endothelial growth factor-D are generated by RNA splicing and proteolysis. J. Biol. Chem. 276:44307-44314.
8. Baldwin, M. E., S. A. Stacker, and M. G. Achen. 2002. Molecular control of lymphangiogenesis. Bioessays 24:1030-1040.
9. Barnett, L. D., and F. Kontgen. 2001. Gene targeting in a centralized facility. Methods Mol. Biol. 158:65-82.
10. Bhardwaj, S., H. Roy, M. Gruchala, H. Viita, I. Kholova, I. Kokina, M. G. Achen, S. A. Stacker, M. Hedman, K. Alitalo, and S. Yla-Herttuala. 2003. Angiogenic responses of vascular endothelial growth factors in periadventitial tissue. Hum. Gene Ther. 14:1451-1562.
11. Dumont, D. J., L. Jussila, J. Taipale, A. Lymboussaki, T. Mustonen, K. Pajusola, M. Breitman, and K. Alitalo. 1998. Cardiovascular failure in mouse embryos deficient in VEGF receptor-3. Science 282:946-949.
12. Gale, N. W., G. Thurston, S. F. Hackett, R. Renard, Q. Wang, J. McClain, C. Martin, C. Witte, M. H. Witte, D. Jackson, C. Suri, P. A. Campochiaro, S. J. Wiegand, and G. D. Yancopoulos. 2002. Angiopoietin-2 is required for postnatal angiogenesis and lymphatic patterning, and only the latter role is rescued by angiopoietin-1. Dev. Cell 3:411-423.
13. Guery, B. P., S. Nelson, N. Viget, P. Fialdes, W. R. Summer, E. Dobard, G. Beaucaire, and C. M. Mason. 1998. Fluorescein-labeled dextran concentration is increased in BAL fluid after ANTU-induced edema in rats. J. Appl. Physiol. 85:842-848.
14. Jansen, L., M. H. Doting, E. J. Rutgers, J. de Vries, R. A. Olmos, and O. E. Nieweg. 2000. Clinical relevance of sentinel lymph nodes outside the axilla in patients with breast cancer. Br. J. Surg. 87:920-925.
15. Jeltsch, M., A. Kaipainen, V. Joukov, X. Meng, M. Lakso, H. Rauvala, M. Swartz, D. Fukumura, R. K. Jain, and K. Alitalo. 1997. Hyperplasia of lymphatic vessels in VEGF-C transgenic mice. Science 276:1423-1425.
16. Jenkins, N. A., E. Woollatt, J. Crawford, D. J. Gilbert, M. E. Baldwin, G. R. Sutherland, N. G. Copeland, and M. G. Achen. 1997. Mapping of the gene for vascular endothelial growth factor-D in mouse and man to the X chromosome. Chromosome Res. 5:502-505.
17. Joukov, V., K. Pajusola, A. Kaipainen, D. Chilov, I. Lahtinen, E. Kukk, O. Saksela, N. Kalkkinen, and K. Alitalo. 1996. A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt-4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases. EMBO J. 15:290-298.
18. Kaipainen, A., J. Korhonen, T. Mustonen, V. W. van Hinsbergh, G. H. Fang, D. Dumont, M. Breitman, and K. Alitalo. 1995. Expression of the fms-like tyrosine kinase 4 gene becomes restricted to lymphatic endothelium during development. Proc. Natl. Acad. Sci. USA 92:3566-3570.
19. Karkkainen, M. J., R. E. Ferrell, E. C. Lawrence, M. A. Kimak, K. L. Levinson, M. A. McTigue, K. Alitalo, and D. N. Finegold. 2000. Missense mutations interfere with VEGFR-3 signalling in primary lymphoedema. Nat. Genet. 25:153-159.
20. Karkkainen, M. J., P. Haiko, K. Sainio, J. Partanen, J. Taipale, T. V. Petrova, M. Jeltsch, D. G. Jackson, M. Talikka, H. Rauvala, C. Betsholtz, and K. Alitalo. 2004. Vascular endothelial growth factor C is required for sprouting of the first lymphatic vessels from embryonic veins. Nat. Immunol. 5:74-80.
21. Karpanen, T., M. Egeblad, M. J. Karkkainen, H. Kubo, S. Ylä-Herttuala, M. Jäättelä, and K. Alitalo. 2001. Vascular endothelial growth factor C promotes tumor lymphangiogenesis and intralymphatic tumor growth. Cancer Res. 61:1786-1790.
22. Kubo, H., T. Fujiwara, L. Jussila, H. Hashi, M. Ogawa, K. Shimizu, M. Awane, Y. Sakai, A. Takabayashi, K. Alitalo, Y. Yamaoka, and S.-I. Nishikawa. 2000. Involvement of vascular endothelial growth factor receptor-3 in maintenance of integrity of endothelial cell lining during tumor angiogenesis. Blood 96:545-553.
23. Kukk, E., A. Lymboussaki, S. Taira, A. Kaipainen, M. Jeltsch, V. Joukov, and K. Alitalo. 1996. VEGF-C receptor binding and pattern of expression with VEGFR-3 suggests a role in lymphatic vascular development. Development 122:3829-3837.
24. Lee, J., A. Gray, J. Yuan, S. M. Luoh, H. Avraham, and W. I. Wood. 1996. Vascular endothelial growth factor-related protein: a ligand and specific activator of the tyrosine kinase receptor Flt4. Proc. Natl. Acad. Sci. USA 93:1988-1992.
25. Leu, A. J., D. A. Berk, F. Yuan, and R. K. Jain. 1994. Flow velocity in the superficial lymphatic network of the mouse tail. Am. J. Physiol. 267:H1507-H1513.
26. Lock, P., F. Casagranda, and A. R. Dunn. 1999. Independent SH2-binding sites mediate interaction of Dok-related protein with RasGTPase-activating protein and Nck. J. Biol. Chem. 274:22775-22784.
27. Lymboussaki, A., T. A. Partanen, B. Olofsson, J. Thomas-Crusells, C. D. M. Fletcher, R. M. W. de Waal, A. Kaipainen, and K. Alitalo. 1998. Expression of the vascular endothelial growth factor C receptor VEGFR-3 in lymphatic endothelium of the skin and in vascular tumors. Am. J. Pathol. 153:395-403.
28. Mäkinen, T., L. Jussila, T. Veikkola, T. Karpanen, M. I. Kettunen, K. J. Pulkkanen, R. Kauppinen, D. G. Jackson, H. Kubo, S. I. Nishikawa, S. Ylä-Herttuala, and K. Alitalo. 2001. Inhibition of lymphangiogenesis with resulting lymphedema in transgenic mice expressing soluble VEGF receptor-3. Nat. Med. 7:199-205.
29. Mandriota, S. J., L. Jussila, M. Jeltsch, A. Compagni, D. Baetens, R. Prevo, S. Banerji, J. Huarte, R. Montesano, D. G. Jackson, L. Orci, K. Alitalo, G. Christofori, and M. S. Pepper. 2001. Vascular endothelial growth factor-C-mediated lymphangiogenesis promotes tumour metastasis. EMBO J. 20:672-682.
30. Mason, C. M., B. P. Guery, W. R. Summer, and S. Nelson. 1996. Keratinocyte growth factor attenuates lung leak induced by alpha- naphthylthiourea in rats. Crit. Care Med. 24:925-931.
31. McColl, B. K., M. E. Baldwin, S. Roufail, C. Freeman, R. L. Moritz, R. J. Simpson, K. Alitalo, S. A. Stacker, and M. G. Achen. 2003. Plasmin activates the lymphangiogenic growth factors VEGF-C and VEGF-D. J. Exp. Med. 198:863-868.
32. Millauer, B., S. Wizigmann-Voos, H. Schnüren, R. Martinez, N. P. H. Moller, W. Risau, and A. Ullrich. 1993. High affinity VEGF binding and developmental expression suggest Flk-1 as a major regulator of vasculogenesis and angiogenesis. Cell 72:835-846.
33. Moore, K. L. 1985. Clinically orientated anatomy. The Williams & Wilkins Co., Baltimore, Md.
34. Nagy, J. A., E. Vasile, D. Feng, C. Sundberg, L. F. Brown, M. J. Detmar, J. A. Lawitts, L. Benjamin, X. Tan, E. J. Manseau, A. M. Dvorak, and H. F. Dvorak. 2002. Vascular permeability factor/vascular endothelial growth factor induces lymphangiogenesis as well as angiogenesis. J. Exp. Med. 196:1497-1506.
35. Orlandini, M., L. Marconcini, R. Ferruzzi, and S. Oliviero. 1996. Identification of a c-fos-induced gene that is related to the platelet-derived growth factor/vascular endothelial growth factor family. Proc. Natl. Acad. Sci. USA 93:11675-11680.
36. Rissanen, T. T., J. E. Markkanen, M. Gruchala, T. Heikura, A. Puranen, M. I. Kettunen, I. Kholová, R. A. Kauppinen, M. G. Achen, S. A. Stacker, K. Alitalo, and S. Ylä-Herttuala. 2003. VEGF-D is the strongest angiogenic and lymphangiogenic effector among VEGFs delivered into skeletal muscle via adenoviruses. Circ. Res. 92:1098-1106.
37. Rutanen, J., T. T. Rissanen, J. E. Markkanen, M. Gruchala, P. Silvennoinen, A. Kivela, A. Hedman, M. Hedman, T. Heikura, M. R. Orden, S. A. Stacker, M. G. Achen, J. Hartikainen, and S. Yla-Herttuala. 2004. Adenoviral catheter-mediated intramyocardial gene transfer using the mature form of vascular endothelial growth factor-D induces transmural angiogenesis in porcine heart. Circulation 109:1029-1035.
38. Sambrook, J., and D. W. Russell. 2001. Molecular cloning: a laboratory manual, 3nd ed. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.
39. Skobe, M., T. Hawighorst, D. G. Jackson, R. Prevo, L. Janes, P. Velasco, L. Riccardi, K. Alitalo, K. Claffey, and M. Detmar. 2001. Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis. Nat. Med. 7:192-198.
40. Stacker, S. A., M. G. Achen, L. Jussila, M. E. Baldwin, and K. Alitalo. 2002. Lymphangiogenesis and cancer metastasis. Nat. Rev. Cancer 2:573-583.
41. Stacker, S. A., M. E. Baldwin, and M. G. Achen. 2002. The role of tumor lymphangiogenesis in metastatic spread. FASEB J. 16:922-934.
42. Stacker, S. A., C. Caesar, M. E. Baldwin, G. E. Thornton, R. A. Williams, R. Prevo, D. G. Jackson, S.-I. Nishikawa, H. Kubo, and M. G. Achen. 2001. VEGF-D promotes the metastatic spread of tumor cells via the lymphatics. Nat. Med. 7:186-191.
43. Stacker, S. A., K. Stenvers, C. Caesar, A. Vitali, T. Domagala, E. Nice, S. Roufail, R. J. Simpson, R. Moritz, T. Karpanen, K. Alitalo, and M. G. Achen. 1999. Biosynthesis of vascular endothelial growth factor-D involves proteolytic processing which generates non-covalent homodimers. J. Biol. Chem. 274:32127-32136.
44. Swartz, M. A., D. A. Berk, and R. K. Jain. 1996. Transport in lymphatic capillaries. I. Macroscopic measurements using residence time distribution theory. Am. J. Physiol. 270:H324-H329.
45. Veikkola, T., L. Jussila, T. Makinen, T. Karpanen, M. Jeltsch, T. V. Petrova, H. Kubo, G. Thurston, D. M. McDonald, M. G. Achen, S. A. Stacker, and K. Alitalo. 2001. Signalling via vascular endothelial growth factor receptor-3 is sufficient for lymphangiogenesis in transgenic mice. EMBO J. 20:1223-1231.
46. Wigle, J. T., and G. Oliver. 1999. Prox1 function is required for the development of the murine lymphatic system. Cell 98:769-778.
47. Yamada, Y., J.-I. Nezu, M. Shimane, and Y. Hirata. 1997. Molecular cloning of a novel vascular endothelial growth factor, VEGF-D. Genomics 42:483-488.